Limits...
Intra-Bone Marrow Transplantation of Endosteal Bone Marrow Cells Facilitates Allogeneic Hematopoietic and Stromal Cells Engraftment Dependent on Early Expression of CXCL-12.

Chen C, Su Y, Chen J, Zhang D, Song Y, Guo S - Med. Sci. Monit. (2015)

Bottom Line: We compared the new method with each control group for allogeneic HSCs homing pattern, peripheral blood chimerism level, skin allograft survival time, and donor stromal cell percentage in recipient BM.By AMD3100 blockade at day 1, peripheral blood chimerism level and donor stromal cell percentage were significantly reduced as compared to the control group without AMD3100 blockade.Our study suggests that IBBMT of endosteal BMCs is an effective approach for HSCT in inducing allogeneic hematopoietic reconstitution.

View Article: PubMed Central - PubMed

Affiliation: Department of Plastic and Reconstructive Surgery, Xijing Hospital, The Fourth Military Medical University, Xi'an, Shaanxi, China (mainland).

ABSTRACT

Background: Hematopoietic stem cell transplantation (HSCT) has been considered as an effective approach at inducing allogeneic hematopoietic reconstitution and immune tolerance. However, it remains critical to find the optimal HSCT delivery method and robust sources of hematopoietic stem cells (HSCs).

Material and methods: We introduced a new method by infusing allogeneic endosteal bone marrow cells (BMCs) harvested from long bones endosteum through intra-bone marrow transplantation (IBBMT) into irradiated mice. Recipient mice that were transplanted with central BMCs or through intravenous bone marrow transplantation (IVBMT) were used as controls (n=6 per group). We compared the new method with each control group for allogeneic HSCs homing pattern, peripheral blood chimerism level, skin allograft survival time, and donor stromal cell percentage in recipient BM. AMD3100 was injected to determine whether chemokine stromal cell-derived factor-1 (CXCL-12) was critical for the new method.

Results: More allogeneic HSCs homed into spleen and bone marrow for the new method as compared to each control group. IBBMT of endosteal BMCs led to a higher peripheral blood chimerism and skin allograft survival. At 18 weeks, donor stromal cell percentage in recipient BMCs was higher for the new method than in each control group. By AMD3100 blockade at day 1, peripheral blood chimerism level and donor stromal cell percentage were significantly reduced as compared to the control group without AMD3100 blockade.

Conclusions: Our study suggests that IBBMT of endosteal BMCs is an effective approach for HSCT in inducing allogeneic hematopoietic reconstitution. The advantage is dependent upon the early expression of CXCL-12 after bone marrow transplantation.

No MeSH data available.


Related in: MedlinePlus

The effects of AMD3100 blockade on peripheral blood chimerism and donor stromal percentage for IB-eBMCs and IB-cBMCs groups. AMD3100 was injected intraperitoneally at 1- or 7-days at 16 mg/kg per mouse for IB-eBMCs (A, B) and IB-cBMCs (C, D) groups. (A, C) The PBMCs chimerism level was assessed at 1-, 6-, 12-, and 18-weeks after BMT. PBMCs chimerism level data for the IB-eBMCs (A) or IB-cBMCs (C) without AMD3100 injection (dashed lines) was taken as the untreated control. All results were represented as Mean ±SD (%), n=6 per group. *, p value of day 1 injection versus untreated control; #, p value of day 7 injection versus untreated control, ns is for not significant. *, #, p<0.05. (B, D). Donor stromal cells percentage in injected and non-injected BM of IB-eBMCs (B) and IB-cBMCs (D) groups with AMD3100 injection at 1 (triangles) or 7 days (quadrilaterals) were analyzed at 18 weeks after BMT as compared with corresponding untreated controls. Each dot is a result of recipient mice and bars are the mean for each group (%).*, p<0.05.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4588631&req=5

f4-medscimonit-21-2757: The effects of AMD3100 blockade on peripheral blood chimerism and donor stromal percentage for IB-eBMCs and IB-cBMCs groups. AMD3100 was injected intraperitoneally at 1- or 7-days at 16 mg/kg per mouse for IB-eBMCs (A, B) and IB-cBMCs (C, D) groups. (A, C) The PBMCs chimerism level was assessed at 1-, 6-, 12-, and 18-weeks after BMT. PBMCs chimerism level data for the IB-eBMCs (A) or IB-cBMCs (C) without AMD3100 injection (dashed lines) was taken as the untreated control. All results were represented as Mean ±SD (%), n=6 per group. *, p value of day 1 injection versus untreated control; #, p value of day 7 injection versus untreated control, ns is for not significant. *, #, p<0.05. (B, D). Donor stromal cells percentage in injected and non-injected BM of IB-eBMCs (B) and IB-cBMCs (D) groups with AMD3100 injection at 1 (triangles) or 7 days (quadrilaterals) were analyzed at 18 weeks after BMT as compared with corresponding untreated controls. Each dot is a result of recipient mice and bars are the mean for each group (%).*, p<0.05.

Mentions: Data acquired so far suggested CXCL-12 may be related with the improved donor hematopoietic and stromal cells engraftment for the IB-eBMCs group. To determine whether the superiority of IBBMT of endosteal BMCs is dependent upon CXCL-12, we injected AMD3100 intraperitoneally at 1 or 7 days for IB-eBMCs and IB-cBMCs groups. As compared with the data from IB-eBMCs or IB-cBMCs groups without AMD3100 blockade (Figure 1A, 1C), AMD3100 injection at 1 day after BMT significantly reduced the PBMCs chimerism level (Figure 4A) assessed at 18 weeks. However, the AMD3100 blockade at 7 day did not reduce PBMCs chimerism level (Figure 4A, 4C).


Intra-Bone Marrow Transplantation of Endosteal Bone Marrow Cells Facilitates Allogeneic Hematopoietic and Stromal Cells Engraftment Dependent on Early Expression of CXCL-12.

Chen C, Su Y, Chen J, Zhang D, Song Y, Guo S - Med. Sci. Monit. (2015)

The effects of AMD3100 blockade on peripheral blood chimerism and donor stromal percentage for IB-eBMCs and IB-cBMCs groups. AMD3100 was injected intraperitoneally at 1- or 7-days at 16 mg/kg per mouse for IB-eBMCs (A, B) and IB-cBMCs (C, D) groups. (A, C) The PBMCs chimerism level was assessed at 1-, 6-, 12-, and 18-weeks after BMT. PBMCs chimerism level data for the IB-eBMCs (A) or IB-cBMCs (C) without AMD3100 injection (dashed lines) was taken as the untreated control. All results were represented as Mean ±SD (%), n=6 per group. *, p value of day 1 injection versus untreated control; #, p value of day 7 injection versus untreated control, ns is for not significant. *, #, p<0.05. (B, D). Donor stromal cells percentage in injected and non-injected BM of IB-eBMCs (B) and IB-cBMCs (D) groups with AMD3100 injection at 1 (triangles) or 7 days (quadrilaterals) were analyzed at 18 weeks after BMT as compared with corresponding untreated controls. Each dot is a result of recipient mice and bars are the mean for each group (%).*, p<0.05.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4588631&req=5

f4-medscimonit-21-2757: The effects of AMD3100 blockade on peripheral blood chimerism and donor stromal percentage for IB-eBMCs and IB-cBMCs groups. AMD3100 was injected intraperitoneally at 1- or 7-days at 16 mg/kg per mouse for IB-eBMCs (A, B) and IB-cBMCs (C, D) groups. (A, C) The PBMCs chimerism level was assessed at 1-, 6-, 12-, and 18-weeks after BMT. PBMCs chimerism level data for the IB-eBMCs (A) or IB-cBMCs (C) without AMD3100 injection (dashed lines) was taken as the untreated control. All results were represented as Mean ±SD (%), n=6 per group. *, p value of day 1 injection versus untreated control; #, p value of day 7 injection versus untreated control, ns is for not significant. *, #, p<0.05. (B, D). Donor stromal cells percentage in injected and non-injected BM of IB-eBMCs (B) and IB-cBMCs (D) groups with AMD3100 injection at 1 (triangles) or 7 days (quadrilaterals) were analyzed at 18 weeks after BMT as compared with corresponding untreated controls. Each dot is a result of recipient mice and bars are the mean for each group (%).*, p<0.05.
Mentions: Data acquired so far suggested CXCL-12 may be related with the improved donor hematopoietic and stromal cells engraftment for the IB-eBMCs group. To determine whether the superiority of IBBMT of endosteal BMCs is dependent upon CXCL-12, we injected AMD3100 intraperitoneally at 1 or 7 days for IB-eBMCs and IB-cBMCs groups. As compared with the data from IB-eBMCs or IB-cBMCs groups without AMD3100 blockade (Figure 1A, 1C), AMD3100 injection at 1 day after BMT significantly reduced the PBMCs chimerism level (Figure 4A) assessed at 18 weeks. However, the AMD3100 blockade at 7 day did not reduce PBMCs chimerism level (Figure 4A, 4C).

Bottom Line: We compared the new method with each control group for allogeneic HSCs homing pattern, peripheral blood chimerism level, skin allograft survival time, and donor stromal cell percentage in recipient BM.By AMD3100 blockade at day 1, peripheral blood chimerism level and donor stromal cell percentage were significantly reduced as compared to the control group without AMD3100 blockade.Our study suggests that IBBMT of endosteal BMCs is an effective approach for HSCT in inducing allogeneic hematopoietic reconstitution.

View Article: PubMed Central - PubMed

Affiliation: Department of Plastic and Reconstructive Surgery, Xijing Hospital, The Fourth Military Medical University, Xi'an, Shaanxi, China (mainland).

ABSTRACT

Background: Hematopoietic stem cell transplantation (HSCT) has been considered as an effective approach at inducing allogeneic hematopoietic reconstitution and immune tolerance. However, it remains critical to find the optimal HSCT delivery method and robust sources of hematopoietic stem cells (HSCs).

Material and methods: We introduced a new method by infusing allogeneic endosteal bone marrow cells (BMCs) harvested from long bones endosteum through intra-bone marrow transplantation (IBBMT) into irradiated mice. Recipient mice that were transplanted with central BMCs or through intravenous bone marrow transplantation (IVBMT) were used as controls (n=6 per group). We compared the new method with each control group for allogeneic HSCs homing pattern, peripheral blood chimerism level, skin allograft survival time, and donor stromal cell percentage in recipient BM. AMD3100 was injected to determine whether chemokine stromal cell-derived factor-1 (CXCL-12) was critical for the new method.

Results: More allogeneic HSCs homed into spleen and bone marrow for the new method as compared to each control group. IBBMT of endosteal BMCs led to a higher peripheral blood chimerism and skin allograft survival. At 18 weeks, donor stromal cell percentage in recipient BMCs was higher for the new method than in each control group. By AMD3100 blockade at day 1, peripheral blood chimerism level and donor stromal cell percentage were significantly reduced as compared to the control group without AMD3100 blockade.

Conclusions: Our study suggests that IBBMT of endosteal BMCs is an effective approach for HSCT in inducing allogeneic hematopoietic reconstitution. The advantage is dependent upon the early expression of CXCL-12 after bone marrow transplantation.

No MeSH data available.


Related in: MedlinePlus